Karo Pharma AB (Karo Pharma AB) Research & Development : $0.0 Mil (TTM As of Jun. 2022)

View and export this data going back to . Start your Free Trial

What is Karo Pharma AB Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. Karo Pharma AB's Research & Development for the three months ended in Jun. 2022 was $0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2022 was $0.0 Mil.

Karo Pharma AB Research & Development Historical Data

The historical data trend for Karo Pharma AB's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karo Pharma AB Research & Development Chart

Karo Pharma AB Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Research & Development

Get a 7-Day Free Trial

0.52

0.07

Karo Pharma AB Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Jun22
Research & Development	Get a 7-Day Free Trial															-	-	-	-	-

Karo Pharma AB Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

Karo Pharma AB (OTCPK:KARBF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Karo Pharma AB Research & Development Related Terms

Thank you for viewing the detailed overview of Karo Pharma AB's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

Karo Pharma AB (Karo Pharma AB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Karo Pharma AB (OTCPK:KARBF) » Definitions » Research & Development

Comparable Companies

Traded in Other Exchanges

N/A

Address

Klara Norra Kyrkogata 33, Stockholm, SWE, 111 22

Website

https://www.karopharma.com

Karo Pharma AB is a healthcare corporation. It is engaged in the business activity of developing and marketing products to pharmacies and directly to the healthcare sector. The trademarks of the firm are Ibux, Paracet, Dosett, Allevo, and Swereco. It operates in the segment of development and sale of products to pharmacies, digital distribution channels and food stores. The company carries its business operations in Sweden and internationally, of which the majority of the revenue is generated from Sweden and Norway.

Karo Pharma AB (Karo Pharma AB) Headlines

From GuruFocus

Avista Capital Partners To Sell Trimb To Karo Pharma

By PRNewswire PRNewswire • 06-25-2019